Direct Biologics, LLC Announces One Year Follow Up of Pilot Safety Study of ExoFlo for Treatment of Osteoarthritis in Combat-Related Injuries Thirty-three Navy SEAL veterans were treated with a bone marrow mesenchymal stem cell (MSC) derived extracellular vesical isolate product (EVIP) for Osteoarthritis (OA) of the knee, shoulder, elbow, hip, ankle, or wrist. AUSTIN, Texas, November 11,… Read More »Direct Biologics, LLC Announces One Year Follow Up of Pilot Safety Study of ExoFlo for Treatment of Osteoarthritis in Combat-Related Injuries

The post Direct Biologics, LLC Announces One Year Follow Up of Pilot Safety Study of ExoFlo for Treatment of Osteoarthritis in Combat-Related Injuries appeared first on Direct Biologics.